Please login to the form below

Not currently logged in
Email:
Password:

gabapentin enacarbil

This page shows the latest gabapentin enacarbil news and features for those working in and with pharma, biotech and healthcare.

US shortage of GSK’s restless legs syndrome treatment Horizant

US shortage of GSK’s restless legs syndrome treatment Horizant

In its notice, the US regulator said GSK is “experiencing a backorder situation”, leaving an expected shortage of Horizant (gabapentin enacarbil) until June 2013 – one month after XenoPort assumes responsibility for

Latest news

  • GSK sales fall for first quarter of 2011

    Recent approvals for GSK include lupus drug Benlysta (belimumab), Horizant (gabapentin enacarbil) for Restless Legs Syndrome and epilepsy treatment Trobalt (retigabine).

  • GSK Restless Legs Syndrome drug approved

    GlaxoSmithKline (GSK) and XenoPort have won marketing approval from the US Food and Drug Administration (FDA) for Horizant (gabapentin enacarbil), a non-dopaminergic treatment for moderate-to-severe primary Restless Legs ... The drug, which was

  • GSK migraine study fails

    The drug, gabapentin enacarbil (GSK1838262/XP13512), is a new chemical entity that provides dose-proportional, sustained exposure of gabapentin using high-capacity transport mechanisms in the gastrointestinal tract.

  • FDA rejects GSK and Xenoport's Horizant

    GSK and XenoPort, have received a Complete Response letter from the US FDA relating to Horizant (gabapentin enacarbil). ... Gabapentin enacarbil is also being developed in partnership with Astellas Pharma for the potential treatment of Restless Legs

  • Deals in development

    Xenoport can expect upwards of USD 640m from GlaxoSmithKline for its phase III restless legs syndrome candidate, gabapentin enacarbil. ... Restless legs syndrome. gabapentin enacarbil. Anacor Pharmaceuticals. Schering-Plough. > 625m. Onychomycosis.

More from news
Approximately 1 fully matching, plus 5 partially matching documents found.

Latest appointments

  • XenoPort appoints chief medical officer XenoPort appoints chief medical officer

    Dr Kim has been with the US biopharma company since July 2013, when he joined as VP of medical affair, supporting the marketing of Horizant (gabapentin enacarbil) in restless legs syndrome

More from appointments
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Say Communications

Influencing positive behaviours and delivering change is what drives us, using thought leadership, education, social and professional engagement and compelling,...

Latest intelligence

Report: Achieving launch excellence in the challenging healthcare markets of today
Our in-depth report is based on original data and expert interviews, which coupled with our own experience, ensures we give you the best recommendations for achieving launch success in challenging...
What is blockchain and why should i care - Richard Springham
Four Health - Emerging Technologies The power of blockchain lies in the fact it can prove that a unique event occurred at a certain time with out the need to...
NHS medicines optimisation milestone
Steve How, Paul Midgley and Oli Hudson, of the Wilmington Healthcare Consulting Team, explore the implications of Adalimumab’s recent European patent expiry...

Infographics